90%Confidence
0Views
FDASource
2026-04-14Date
Summary
Additional sterility failures for K.C. Pharmaceuticals' lubricating eye drops indicate systemic manufacturing quality issues. The involvement of major distributors like Cardinal Health amplifies the market impact and regulatory exposure.
Actionable: Remove all K.C. Pharmaceuticals eye drop products from inventory until sterility assurance is verified.
AI Confidence: 90%
Data Points
firmK.C. Pharmaceuticals, Inc
classificationClass II
statusOngoing
distributionNationwide in the US
productUltra Lubricating Eye Drops (polyethylene 400 0.4%, propylene glycol 0.3%), Sterile, 0.5 FL OZ (15mL) bottles; a) LEADER, DISTRIBUTED BY CARDINAL HEAL
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now